gastro-retentivedrugdeliverysystem B.PHARM.pptx

sana916816 63 views 36 slides May 02, 2024
Slide 1
Slide 1 of 36
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36

About This Presentation

Gastro-retentive delivery is one of the site specific delivery of the drugs at stomach.


Slide Content

GASTRO-RETENTIVE DRUG DELIVERY SYSTEM

CONTENTS 2 Introduction Gastrointestinal tract physiology Potential candidates for GRDDS Factors affecting GRDDS Merits and Demerits Approaches for GRDDS Methodology Evaluation parameters Applications Marketed formulations

INT R ODUCT I ON Gastroretentive drug delivery is an approach to prolong gastric residence time, there by targeting site-specific drugs release in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form into stomach and by releasing the in controlled manner. 3

GASTROINTEST I NAL TRA C T PHYSIOLOGY 4 Migrating myoelectric cycle

POT E NTI AL CA N DI D A TES FOR GRDDS 5 Drugs acting locally in the stomach. E.g. Antacids and drugs for H. Pylori viz., Misoprolol. Drugs that are primarily absorbed in the stomach. E.g . A m oxici l l i n Drugs that is poorly soluble at alkaline pH. E.g. Furosemide, Diazepam, Verampil, etc. Drugs with a narrow absorption window. E.g. Cyclosporine, Levodopa, Methotrexate etc.

Drugs which are absorbed rapidly from the GI tract. E.g. Metronidazole, tetracycline. Drugs that degrade in the colon. E.g. Ranitidine, Metformin. Drugs that disturb normal colonic microbes. E .g. Antib i ot i c s aga i nst H . Py l or i. Drugs with less half life. 6

DRUG CANDIDATES NOT SUITABLE FOR GRDDS 7 Drugs that have very limited acid solubility. E.g. Phenytoin, etc. Drugs that suffer instability in the gastric environment. E.g. Erythromycin, etc. Drugs intended for selective release in the colon. E.g. 5-Amino salicylic acid and corticosteroids, etc. Drugs having extensive first pass metabolism.

F AC T ORS AFFECTING THE GRDDS 8 Density Size and Shape of the dosage form Single or Multi unit formulation Age Gender Body posture Frequency of intake Diseased state of an individual

MERITS Improved drug absorption. Enhanced bioavailability. Reduced dose frequency. Controlled drug delivery of drugs. Minimized mucosal irritation. Local action. Better patient compliance. Site specific drug delivery. 9

DEMERITS 10 Drugs that cause gastric lesions. E.g. NSAIDs. Drugs that undergo first pass metabolism. E.g. Nifedipine. Drugs that have very limited acid solubility and stability. E.g. Phenytoin. Drugs that degrade in acidic environment. Drugs which are well absorbed along the entire GIT. Requires high levels of fluids in stomach. Requires presence of food to delay gastric emptying.

11

APPROACHES TO GASTRIC RETENSION High density system Low density system Mucoadhesive system Raft forming system Swellable system Superporous hydrogels Self unfolding systems 12

13

A. FLOATING DRUG DELIVERY SYSTEMS Floating drug delivery systems have a bulk density lower than gastric fluids and thus remain buoyant in the stomach for prolonged period of time, without affecting the gastric emptying rate. While the system is floating on the gastric contents, the drug is released slowly at a desired rate from the system. This type is also called as hydro dynamically balanced system (HBS). 14

MECHANISM OF FDDS FDDS has a bulk density less than gastric fluids and soremain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. F= buoyancy- gravity = (D f -Ds)gv Where,F= total vertical force, Df= fluid density, Ds= object density, v = volume, g = acceleration due to gravity. 15

TYPES O F FLO A TING SYST E M 16

Effervescent system: This are low density FDDS is based on the formation of CO 2 within the device following contact with the body. 17

Non effervescent system: This system use a gel forming (or) swellable cellulose type of Hydrocolloids, polysaccharide, matrix forming polymer like polycarbonate, polystyrene and polymethacrylate. One of the formulation methods involves the mixing of the drug with gelforming hydrocolloids. 18

This hydrocolloids swell in contact with gastric fluid after oral administration and maintains integrity of shape and a bulk density barrier, the air trapped by swollen polymer confer buoyancy to the dosage forms. 19

RAFT FORMING SYSTEM This system is used for delivery of antacids and drug delivery for treatment of gastrointestinal infections and disorders. The mechanism involved in this system includes the formation of a viscous cohesive gel in contact with gastric fluids, forming a continuous layer called raft. 20

MICROPOROUS COMPARTMENT SYSTEM This technology is based on the encapsulation of a drug reservoir inside a microporous compartment with pores along its top and bottom walls. The peripheral wall of the drug reservoir compartment is completely sealed to prevent any direct contact of gastric surface with the undissolved drug. 21

ALGINATE BEADS It is prepared by dropping sodium alginate solution into solution of calcium chloride, causing the precipitates of calcium alginate. Freeze dry in liquid nitrogen at -40ºc for 24 hrs. Formation of porous system which can maintain a floating force over 12 hrs. 22

MICROS P HERES l o aded with d rugs solvent diffusion/ Microballons/ hollow microspheres prep a red b y solvent evapor a t i on or evaportaion methods. Buoyancy and drugs release depends on qual i ty of polymers, plasticizer polymer and solvents used. 23

MAGNETIC SYSTEM This approach to enhance the GRT is based on the simple principle that the dosage form contains a small internal magnet, and a magnet placed on the abdomen over the position of the stomach. Although magnetic system seems to work, the external magent must be positioned with a degree of precision that might compromise patient compliance. 24

B. HIGH DENSITY SYSTEM Gastric contents have a density close to water. A density close to 2.5g/cm 3 is necessary for significant prolongation of gastric residence time. The commonly used excipients in high density system includes barium sulphate, zinc oxide, iron powder, and titanium dioxide. The major drawback with such systems is that it is technically difficult to manufacture them with a large amount of drug (>50%) and to achieve the required density. 25

C. BIOADHESIVE OR MUCOADHESIVE SYSTEM 26 Bio/ muco-adhesive are those which bind to the gastric epithelial cell surface or mucin and serve as a potential means of extending the GRT of drug delivery system (DDS) in the stomach,by interesting the intimacy and duration of contact of drug with the biological membrance. The basis of adhesion in that a dosage form can stick to the mucosal surface by different mechanism. These mechanism are:

1. The wetting theory. The diffusion theory. The absorption theory. The electron theory. P O L YMER 27 MUCUS ME M BR A NE

D. SWELLABLE SYSTEMS These are dosage forms which after swallowing, swell to an extent that prevents their exit from the pylorus. As a result, the dosage form is retained in stomach for a long period of time. These systems may be named as “plug type system”, since they exhibit tendency to remain logged at the pyloric sphincter. 28

E. SUPERPOROUS HYDROGELS Superporous hydrogel in dry state. Superporous hydrogel in water swollen state. On the right, schematic illustration of the transit or superporous hydrogels 29

Swellable agents with pore size ranging between 10nm and 10µm, absorption of water by conventional hydrogel is very slow process and several hours may be needed to reach as equilibrium state during which premature evacuation of the dosage form may occur. Superporous hydrogels swell to equilibrium size with in a minute, due to rapid water uptake by capillary wetting through numerous interconnected open pores. 30

F. SELF UNFOLDING SYSTEM These systems are made of biodegradable polymers and are capable of being mechanically increased in size relative to the initial dimensions. After being swallowed, these dosage forms swell to a size that prevents their passage though rough the pylorus and therefore, the dosage form is prone to be retained in the stomach for a long period of time. 31

METH O DOLO G Y 32 Direct compression method Melt granulation technique Effervescent technique Spray drying technique Solvent evaporation technique Wet granulation technique Ionotropic gelation technique

EVALUATION PARAMETERS 33 Pre- compression test: Size and shape Particle size Density Specific gravity Flow properties Post compression test: Thickness and diameter Hardness and friability Weight variation test floating time Content uniformity Dissolution test Mucoadhesive test

IN VITRO TEST: 34 Floating lag time Floating time Dissolution study Swelling index Mucoadhesive test Densi ty IN VIVO TEST: Radiology Scintigraphy Gastroscopy Magnetic marker monitoring Ult r asonog raphy

APPLICATIONS 35 Enhanced bioavailability Sustained drug delivery Site specific drug delivery system Absorption enhancement Minimized adverse activity at the colon Reduced fluctuation of drug concentration

MARKETED FORMULATIONS 36